-
ScienceDaily
May 29, 2015, 2:47 pm26 ptsImmunotherapy with the anti-PD-1 antibody pembrolizumab decreased the size of tumors by 30 percent or more in 24.8 percent of 132 patients with recurrent or metastatic head and neck cancer. That's nearly twice as effective as the current preferred treatment.
Trending Today on EcoTopical
Welcome to EcoTopical Your daily eco-friendly green news aggregator.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.